We’re pleased to share this letter and news from our partner Santhera about their plans for 2019! For more than 10 years, Santhera has been working on treatments for DMD, and 2019 will bring more clinical trials and research for our community. We’re proud to have Santhera as a partner and look forward to seeing what they achieve this year!
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
How to Identify and Manage Fat Embolism Syndrome (FES) in Fractures
Finding the Right One: Advice from Experts on Dating with a Disability
REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial
Make an Impact
You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.Donate